Boston Family Office’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.66M | Buy |
10,401
+1,234
| +13% | +$440K | 0.24% | 87 |
|
|
2025
Q4 | $3M | Sell |
9,167
-7
| -0.1% | -$2.22K | 0.19% | 95 |
|
|
2025
Q3 | $2.59M | Buy |
9,174
+62
| +0.7% | +$18K | 0.16% | 104 |
|
|
2025
Q2 | $2.54M | Buy |
9,112
+1,056
| +13% | +$299K | 0.17% | 101 |
|
|
2025
Q1 | $2.51M | Sell |
8,056
-178
| -2% | -$52.6K | 0.18% | 100 |
|
|
2024
Q4 | $2.15M | Sell |
8,234
-130
| -2% | -$38.6K | 0.15% | 108 |
|
|
2024
Q3 | $2.69M | Sell |
8,364
-52
| -0.6% | -$17K | 0.18% | 98 |
|
|
2024
Q2 | $2.63M | Sell |
8,416
-52
| -0.6% | -$15.3K | 0.19% | 97 |
|
|
2024
Q1 | $2.41M | Sell |
8,468
-47
| -0.6% | -$13.8K | 0.17% | 99 |
|
|
2023
Q4 | $2.45M | Sell |
8,515
-84
| -1% | -$22.9K | 0.18% | 95 |
|
|
2023
Q3 | $2.31M | Buy |
8,599
+119
| +1% | +$29.7K | 0.19% | 96 |
|
|
2023
Q2 | $1.88M | Buy |
8,480
+78
| +0.9% | +$18.1K | 0.14% | 114 |
|
|
2023
Q1 | $2.03M | Sell |
8,402
-140
| -2% | -$34.4K | 0.16% | 111 |
|
|
2022
Q4 | $2.24M | Sell |
8,542
-279
| -3% | -$74.8K | 0.19% | 103 |
|
|
2022
Q3 | $1.99M | Sell |
8,821
-579
| -6% | -$140K | 0.18% | 101 |
|
|
2022
Q2 | $2.29M | Sell |
9,400
-120
| -1% | -$29.4K | 0.19% | 102 |
|
|
2022
Q1 | $2.3M | Buy |
9,520
+185
| +2% | +$42.5K | 0.16% | 108 |
|
|
2021
Q4 | $2.1M | Buy |
9,335
+51
| +0.5% | +$10.8K | 0.14% | 117 |
|
|
2021
Q3 | $1.97M | Sell |
9,284
-10
| -0.1% | -$2.3K | 0.14% | 116 |
|
|
2021
Q2 | $2.27M | Hold |
9,294
| – | – | 0.16% | 109 |
|
|
2021
Q1 | $2.37M | Sell |
9,294
-1,007
| -10% | -$240K | 0.18% | 108 |
|
|
2020
Q4 | $2.37M | Hold |
10,301
| – | – | 0.18% | 105 |
|
|
2020
Q3 | $2.62M | Sell |
10,301
-398
| -4% | -$98.6K | 0.24% | 87 |
|
|
2020
Q2 | $2.52M | Sell |
10,699
-225
| -2% | -$51.3K | 0.25% | 90 |
|
|
2020
Q1 | $2.21M | Buy |
10,924
+299
| +3% | +$65.3K | 0.26% | 89 |
|
|
2019
Q4 | $2.56M | Sell |
10,625
-93
| -0.9% | -$20.5K | 0.24% | 94 |
|
|
2019
Q3 | $2.07M | Buy |
10,718
+102
| +1% | +$19.6K | 0.22% | 103 |
|
|
2019
Q2 | $1.96M | Sell |
10,616
-25
| -0.2% | -$4.48K | 0.2% | 107 |
|
|
2019
Q1 | $2.02M | Sell |
10,641
-20
| -0.2% | -$3.82K | 0.22% | 103 |
|
|
2018
Q4 | $2.08M | Buy |
10,661
+46
| +0.4% | +$8.97K | 0.26% | 100 |
|
|
2018
Q3 | $2.2M | Sell |
10,615
-160
| -1% | -$31.5K | 0.23% | 105 |
|
|
2018
Q2 | $1.99M | Sell |
10,775
-395
| -4% | -$69.9K | 0.23% | 111 |
|
|
2018
Q1 | $1.9M | Sell |
11,170
-755
| -6% | -$139K | 0.22% | 114 |
|
|
2017
Q4 | $2.07M | Sell |
11,925
-75
| -0.6% | -$13.3K | 0.23% | 111 |
|
|
2017
Q3 | $2.24M | Hold |
12,000
| – | – | 0.25% | 108 |
|
|
2017
Q2 | $2.07M | Sell |
12,000
-2,450
| -17% | -$398K | 0.24% | 108 |
|
|
2017
Q1 | $2.37M | Sell |
14,450
-500
| -3% | -$83.1K | 0.29% | 95 |
|
|
2016
Q4 | $2.19M | Sell |
14,950
-150
| -1% | -$22.6K | 0.28% | 97 |
|
|
2016
Q3 | $2.52M | Sell |
15,100
-500
| -3% | -$84.6K | 0.33% | 89 |
|
|
2016
Q2 | $2.37M | Sell |
15,600
-960
| -6% | -$149K | 0.31% | 93 |
|
|
2016
Q1 | $2.48M | Buy |
16,560
+8,135
| +97% | +$1.21M | 0.33% | 91 |
|
|
2015
Q4 | $1.37M | Hold |
8,425
| – | – | 0.19% | 126 |
|
|
2015
Q3 | $1.17M | Hold |
8,425
| – | – | 0.16% | 132 |
|
|
2015
Q2 | $1.29M | Hold |
8,425
| – | – | 0.16% | 133 |
|
|
2015
Q1 | $1.35M | Sell |
8,425
-75
| -0.9% | -$11.8K | 0.17% | 133 |
|
|
2014
Q4 | $1.35M | Sell |
8,500
-75
| -0.9% | -$11.7K | 0.17% | 132 |
|
|
2014
Q3 | $1.2M | Hold |
8,575
| – | – | 0.15% | 132 |
|
|
2014
Q2 | $1.01M | Hold |
8,575
| – | – | 0.13% | 151 |
|
|
2014
Q1 | $1.06M | Hold |
8,575
| – | – | 0.14% | 142 |
|
|
2013
Q4 | $978K | Sell |
8,575
-250
| -3% | -$28.4K | 0.13% | 150 |
|
|
2013
Q3 | $988K | Sell |
8,825
-100
| -1% | -$10.8K | 0.14% | 142 |
|
|
2013
Q2 | $881K | Buy |
+8,925
| New | +$926K | 0.13% | 145 |
|
Other funds holding AMGN
VCM
VPM
Boston Family Office's AMGN Position: Q1 2026 in Review
Boston Family Office increased its Amgen (AMGN) stake by 13% in Q1 2026, buying an estimated $440K and bringing the position to 10,401 shares worth $3.66M. The position accounts for 0.24% of the portfolio, ranked #87.
Boston Family Office first reported a position in AMGN in Q2 2013 and has held it in 52 quarters since. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.
- Boston Family Office held 10,401 shares of Amgen worth $3.66M as of Q1 2026.
- Boston Family Office bought 1,234 Amgen shares in Q1 2026, an estimated $440K.
- Amgen made up 0.24% of Boston Family Office's portfolio in Q1 2026, its #87 holding.
- Boston Family Office first reported a position in Amgen in Q2 2013 and has held it in 52 quarters since.
- 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.
Based on Boston Family Office's 13F filing for Q1 2026, filed 13 May 2026.